Humacyte Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Humacyte Inc (HUMA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Humacyte Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 30M vs 658M combined for tracked competitors (4.4% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-163.2% annualized vs trailing 12 months), vs decelerating (-11.2%) for its tracked peer group.
- Scale: Humacyte Inc ranks #102 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.16M compares with $0.37M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Humacyte Inc vs. its Competitors, Q2 2026
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Humacyte Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Humacyte Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Humacyte Inc's competitor groups requires a Commercial License.
Humacyte Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Humacyte Inc | No | Yes | Yes | No |
| Competitors combined (12) | ||||
| High-Confidence Competitors (1) | - | |||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
HUMA Stock Performance relative to its Competitors
HUMA Stock Performance relative to High-Confidence Competitors
HUMA Stock Performance relative to Similar-Size Competitors
HUMA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Fate Therapeutics Inc | 282.9% | Outperformed |
| 2 | Brainstorm Cell Therapeutics inc | 282.9% | Outperformed |
| 3 | Aura Biosciences Inc | 282.9% | Outperformed |
| 4 | Mesoblast Limited | 282.9% | Outperformed |
| 5 | Regenxbio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Humacyte Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Humacyte Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Humacyte Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Humacyte Inc | 128.14 | 30.07 |
| Mesoblast Limited | 1,751.30 | 17.20 |
| Aura Biosciences Inc | 583.41 | - |
| Regenxbio Inc | 396.03 | 174.48 |
| Ocugen Inc | 348.84 | 4.58 |
| Fate Therapeutics Inc | 286.55 | 6.49 |
| SUBTOTAL | 3,999.04 | 815.73 |
Sign in to see all competitors of Humacyte Inc .
Sources: Humacyte Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Humacyte Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Humacyte Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Harvard Apparatus Regenerative Technology Inc | Named by the company | 85% |
| Terumo Medical Systems | Named by the company | 85% |
| Hancock Jaffe | Named by the company | 85% |
| Xeltis AG | Named by the company | 85% |
| Atrium (Maquet Getinge Group) | Named by the company | 85% |
| Vascudyne Inc. | Named by the company | 85% |
| NovaHep AB | Named by the company | 85% |
| Bard Peripheral Vascular, Inc. | Named by the company | 85% |
| W.L. Gore & Associates, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Humacyte Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Humacyte Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Humacyte Inc | 128 | 163,446 | -525,734 |
| Mesoblast Limited | 1,751 | 159,241 | -945,759 |
| Aura Biosciences Inc | 583 | - | -1,159,389 |
| Regenxbio Inc | 396 | 470,302 | -529,466 |
| Ocugen Inc | 349 | 39,483 | -705,267 |
| Fate Therapeutics Inc | 287 | 40,317 | -782,584 |
| PEERS TOTAL | 3,871 | 372,526 | -312,017 |
Humacyte Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Humacyte Inc's industry classification, broader than the peer set above. Market cap in millions of $.Humacyte Inc ranks #102 of 159 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,331, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 226,707 | 26.02 % |
| 2 | Gilead Sciences Inc | 185,928 | 21.34 % |
| 3 | Moderna Inc | 76,517 | 8.78 % |
| 4 | Argenx Se | 63,326 | 7.27 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 102 | Humacyte Inc | 130 | 0.01 % |
Market cap and industry share for the rest of Humacyte Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Humacyte Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 97 | Cardiol Therapeutics inc | 145 | 54.63 % |
| 98 | Innate Pharma Sa | 143 | -9.24 % |
| 99 | Entera Bio Ltd | 135 | 49.94 % |
| 100 | Engene Therapeutics Inc | 135 | -70.31 % |
| 101 | Tenaya Therapeutics Inc | 1,234 | 12.3% |
| 102 | Humacyte Inc | 130 | -65.61 % |
| 103 | Neumora Therapeutics Inc | 1,234 | 12.3% |
| 104 | Caribou Biosciences Inc | 1,234 | 12.3% |
| 105 | Atara Biotherapeutics Inc | 1,234 | 12.3% |
| 106 | Lenz Therapeutics Inc | 1,234 | 12.3% |
| 107 | Vaxart Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Humacyte Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Humacyte Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 68.46 % (avg) | - |
| Operating Margin | -369.61 % | industry median | -164.7 pp |
| EBITDA Margin | -286.43 % | -0.94 % (avg) | -285.5 pp |
| Capital Intensity (Capex / Revenue) | 1.22 % | 6.74 % (avg) | -5.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Humacyte Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 20.8x | 5.1x | +15.7x |
| Return on Equity | -938.20 % | industry aggregate | -934.77 % |
| Return on Invested Capital | -105.19 % | -6.17 % (avg) | -99.02 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Humacyte Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | 500.00 % |
| Operating Margin | - | - | - | -2,922.04 % | -265.02 % |
| Return on Invested Capital | - | -24.76 % | -53.06 % | -126.72 % | -93.50 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Humacyte Inc's Strategic Group Map
Every company in Humacyte Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Humacyte Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Humacyte Inc's BCG Growth-Share Matrix
Relative market share (vs Humacyte Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Humacyte Inc falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 10.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Humacyte Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,331 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.22 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Humacyte Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Humacyte Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Humacyte Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Humacyte Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Humacyte Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 164.7 points below the industry median.
- Return on equity 934.8 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-163.2% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-11.2% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Humacyte Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Humacyte Inc | 2.64 | 3.54 | 3.18 |
| Mesoblast Limited | 1.57 | 1.99 | 0.09 |
| Aura Biosciences Inc | 3.53 | 10.44 | - |
| Regenxbio Inc | 0.54 | 2.61 | - |
| Ocugen Inc | 0.93 | 1.05 | - |
| Fate Therapeutics Inc | 2.20 | 6.02 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Humacyte Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Humacyte Inc | Q2 2026 | - | - |
| Mesoblast Limited | Q2 2025 | +191.4 % | - |
| Aura Biosciences Inc | Q2 2026 | - | - |
| Regenxbio Inc | Q2 2026 | +405.7 % | - |
| Ocugen Inc | Q2 2026 | +8.4 % | - |
| Fate Therapeutics Inc | Q2 2026 | +9.2 % | - |
| PEERS TOTAL | +30.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Humacyte Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Humacyte Inc | Q2 2026 | +477.9 % | -81.7 % |
| Mesoblast Limited | Q2 2025 | - | +150.9 % |
| Aura Biosciences Inc | Q2 2026 | - | -46.2 % |
| Regenxbio Inc | Q2 2026 | - | +94.4 % |
| Ocugen Inc | Q2 2026 | - | -51.2 % |
| Fate Therapeutics Inc | Q2 2026 | - | -94.1 % |
Humacyte Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Humacyte Inc | - | - | - |
| Mesoblast Limited | - | - | - |
| Aura Biosciences Inc | - | - | - |
| Regenxbio Inc | - | - | - |
| Ocugen Inc | - | - | - |
| Fate Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Humacyte Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Humacyte Inc | - | 4.26 |
| Mesoblast Limited | - | 101.83 |
| Aura Biosciences Inc | - | - |
| Regenxbio Inc | - | 2.27 |
| Ocugen Inc | - | 76.17 |
| Fate Therapeutics Inc | - | 44.15 |
| PEERS AVERAGE | - | 4.90 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.